Forecasting antimicrobial resistance evolution.

IF 14 1区 生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Trends in Microbiology Pub Date : 2024-08-01 Epub Date: 2024-01-18 DOI:10.1016/j.tim.2023.12.009
Jens Rolff, Sebastian Bonhoeffer, Charlotte Kloft, Rasmus Leistner, Roland Regoes, Michael E Hochberg
{"title":"Forecasting antimicrobial resistance evolution.","authors":"Jens Rolff, Sebastian Bonhoeffer, Charlotte Kloft, Rasmus Leistner, Roland Regoes, Michael E Hochberg","doi":"10.1016/j.tim.2023.12.009","DOIUrl":null,"url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is a major global health issue. Current measures for tackling it comprise mainly the prudent use of drugs, the development of new drugs, and rapid diagnostics. Relatively little attention has been given to forecasting the evolution of resistance. Here, we argue that forecasting has the potential to be a great asset in our arsenal of measures to tackle AMR. We argue that, if successfully implemented, forecasting resistance will help to resolve the antibiotic crisis in three ways: it will (i) guide a more sustainable use (and therefore lifespan) of antibiotics and incentivize investment in drug development, (ii) reduce the spread of AMR genes and pathogenic microbes in the environment and between patients, and (iii) allow more efficient treatment of persistent infections, reducing the continued evolution of resistance. We identify two important challenges that need to be addressed for the successful establishment of forecasting: (i) the development of bespoke technology that allows stakeholders to empirically assess the risks of resistance evolving during the process of drug development and therapeutic/preventive use, and (ii) the transformative shift in mindset from the current praxis of mostly addressing the problem of antibiotic resistance a posteriori to a concept of a priori estimating, and acting on, the risks of resistance.</p>","PeriodicalId":23275,"journal":{"name":"Trends in Microbiology","volume":null,"pages":null},"PeriodicalIF":14.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.tim.2023.12.009","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial resistance (AMR) is a major global health issue. Current measures for tackling it comprise mainly the prudent use of drugs, the development of new drugs, and rapid diagnostics. Relatively little attention has been given to forecasting the evolution of resistance. Here, we argue that forecasting has the potential to be a great asset in our arsenal of measures to tackle AMR. We argue that, if successfully implemented, forecasting resistance will help to resolve the antibiotic crisis in three ways: it will (i) guide a more sustainable use (and therefore lifespan) of antibiotics and incentivize investment in drug development, (ii) reduce the spread of AMR genes and pathogenic microbes in the environment and between patients, and (iii) allow more efficient treatment of persistent infections, reducing the continued evolution of resistance. We identify two important challenges that need to be addressed for the successful establishment of forecasting: (i) the development of bespoke technology that allows stakeholders to empirically assess the risks of resistance evolving during the process of drug development and therapeutic/preventive use, and (ii) the transformative shift in mindset from the current praxis of mostly addressing the problem of antibiotic resistance a posteriori to a concept of a priori estimating, and acting on, the risks of resistance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预测抗菌药耐药性的演变。
抗菌药耐药性(AMR)是一个重大的全球健康问题。目前的应对措施主要包括谨慎用药、开发新药和快速诊断。人们对耐药性演变的预测关注相对较少。在此,我们认为,预测有可能成为我们应对 AMR 的措施库中的一项重要资产。我们认为,如果能够成功实施,抗药性预测将有助于从三个方面解决抗生素危机:(i) 指导更可持续地使用抗生素(从而延长抗生素的寿命),激励对药物开发的投资;(ii) 减少 AMR 基因和病原微生物在环境中和病人之间的传播;(iii) 更有效地治疗顽固性感染,减少抗药性的持续演变。我们发现,要成功建立预测机制,需要应对两个重要挑战:(i) 开发定制技术,使利益相关者能够在药物开发和治疗/预防使用过程中对耐药性演变的风险进行经验评估;(ii) 转变观念,从目前主要在事后解决抗生素耐药性问题的做法转变为事先估计耐药性风险并采取相应行动的理念。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Trends in Microbiology
Trends in Microbiology 生物-生化与分子生物学
CiteScore
25.30
自引率
0.60%
发文量
193
审稿时长
6-12 weeks
期刊介绍: Trends in Microbiology serves as a comprehensive, multidisciplinary forum for discussing various aspects of microbiology, spanning cell biology, immunology, genetics, evolution, virology, bacteriology, protozoology, and mycology. In the rapidly evolving field of microbiology, technological advancements, especially in genome sequencing, impact prokaryote biology from pathogens to extremophiles, influencing developments in drugs, vaccines, and industrial enzyme research.
期刊最新文献
Short-chain fatty acids in viral infection: the underlying mechanisms, opportunities, and challenges. Bacteria-derived short-chain fatty acids as potential regulators of fungal commensalism and pathogenesis. Neutrophils - an understudied bystander in dengue? C4 cereal and biofuel crop microbiomes. Linking microbiome temporal dynamics to host ecology in the wild.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1